Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC.
From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus.
Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 (25%) chromophobe, 2 (5%) collecting duct, 1 (2%) Xp11.2 translocation, and 6 (14%) others. The median PFS and OS were 7.6 and 17.6 months, respectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (HR 0.16; 95% confidence interval [CI], 0.06 to 0.42; p<0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p<0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12, p=0.005] and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56, p=0.015]).
Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.
Cancer research and treatment : official journal of Korean Cancer Association. 2019 Apr 16 [Epub ahead of print]
Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Division of Medical Oncology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea., Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea., Department of Internal Medicine, Chungnam National University, Daejeon, Korea., Division of Hematology-Oncology, Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea., Division of Hematology-Oncology, Pusan National University, Pusan, Korea., Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea., Department of Preventive Medicine and Institute of Health Services Research, Yonsei University College of Medicine, Seoul, Korea., Division of Pathology, Yonsei University College of Medicine, Seoul, Korea.